Rituximab Market Players:
- Amgen Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Henlius Biotech, Inc.
- Nordic Nanovector ASA
- Biocon Biologics Ltd
- Pfizer Inc.
- Chugai Pharmaceuticals
- Zenyaku Kogyo Co. Ltd,
- SymBio Pharmaceuticals
- Daiichi Sankyo
- Kyowa Kirin Co. Ltd
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of rituximab is evaluated at USD 5.84 billion.
The global rituximab market size was worth over USD 5.11 billion in 2025 and is poised to grow at a CAGR of around 15.8%, reaching USD 22.16 billion revenue by 2035.
By 2035, North America is projected to command a 45% share in the Rituximab Market, sustained by rising government allocations for cancer research and the strong presence of leading pharmaceutical companies.
Key players in the market include Amgen Inc, Henlius Biotech, Inc., Nordic Nanovector ASA, Biocon Biologics Ltd, Pfizer Inc., Chugai Pharmaceuticals, Zenyaku Kogyo Co. Ltd, SymBio Pharmaceuticals, Daiichi Sankyo, Kyowa Kirin Co. Ltd.
